A multicenter phase 1/2a dose-escalation study of the antioxidant moiety of vitamin E 2,2,5,7,8-pentamethyl-6-chromanol (APC-100) in men with advanced prostate cancer

Kyriakopoulos, Christos E.; Heath, Elisabeth I.; Eickhoff, Jens; Kolesar, Jill; Yayehyirad, Mulusew; Moll, Thomas; Wilding, George; Liu, Glenn

doi:10.1007/s10637-016-0334-y

Cited by 9 publications

(7 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…APC-100 exhibits anti-androgenic properties, and preclinical studies have observed potent androgen receptor (AR) signaling modulation and anti-cancer activity against PCa cell lines ( 70 ). Recently, Kyriakopoulos et al ( 71 ) tested APC-100 in 20 patients with CRPC and determined that the drug was safe. PSA stabilization in these patients was a sign of drug activity despite suboptimal ( 71 ).…”

Section: Evidence Synthesismentioning

confidence: 99%

See 1 more Smart Citation

Oxidative stress and prostatic diseases

Roumeguère

Sfeir

Rassy

et al. 2017

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Prostatic diseases are a common health problem among males in Western countries, and include chronic prostatic diseases, which have an unclear pathogenesis and few treatment options. In vitro and in vivo studies describe oxidative stress as a major pathway involved in the occurrence of benign prostatic hyperplasia, prostatic cancer and chronic prostatitis. Thus, the oxidative stress cascade is a potential target for the treatment of prostatic diseases. This paper presents a systematic review of the available data concerning the association between oxidative stress and the most common chronic prostatic diseases, and describes the available treatment options that act upon this pathway.

show abstract

Section: Evidence Synthesismentioning

confidence: 99%

“…Recently, Kyriakopoulos et al ( 71 ) tested APC-100 in 20 patients with CRPC and determined that the drug was safe. PSA stabilization in these patients was a sign of drug activity despite suboptimal ( 71 ).…”

Section: Evidence Synthesismentioning

confidence: 99%

Oxidative stress and prostatic diseases

Roumeguère

Sfeir

Rassy

et al. 2017

Molecular and Clinical Oncology

View full text Add to dashboard Cite

show abstract

“…In subsequent studies, researchers have explored using other forms of vitamin E against PCa. An example of this is a phase 1/2a dose escalation study using the antioxidant moiety of vitamin E (2,2,5,7,8-Pentamethyl-6-chromanol) [39]. This study was undertaken to determine, in part, the maximum tolerated dose (MTD) and efficacy in men with CRPC.…”

Section: Pca Clinical Trials With Natural Chemopreventive Agentsmentioning

confidence: 99%

“…To this end, twenty patients with CRPC were administered between 900–2400 mg of vitamin E orally once daily continuously for 28 days. The study found that five of the 20 patients had stable disease as their best response, and median progression free survival (PFS) for the cohort was 2.8 months [39]. Combined with previous vitamin E successes, these results give renewed hope for using vitamin E for PCa chemoprevention, both alone and in combination with other agents.…”

Section: Pca Clinical Trials With Natural Chemopreventive Agentsmentioning

confidence: 99%

Prostate cancer chemoprevention by natural agents: Clinical evidence and potential implications

et al. 2018

View full text Add to dashboard Cite

Prostate cancer (PCa) is the most common non-skin cancer and the second leading cause of cancer-related deaths in American men. Due to its long latency period, PCa is considered as an ideal cancer type for chemopreventive interventions. Chemopreventive agents include various natural or synthetic agents that prevent or delay cancer development, progression and/or recurrence. Pre-clinical studies suggest that many natural products and dietary agents have chemopreventive properties. However, a limited number of these agents have been tested in clinical trials, with varying success. In this review, we have discussed the available clinical studies regarding the efficacy of natural chemopreventive agents against PCa, including tea polyphenols, selenium, soy proteins, vitamins and resveratrol. We have also provided a discussion on the clinical challenges and opportunities for the potential use of chemopreventive agents against PCa. Based on available literature, it appears that the variable outcomes of the chemopreventive clinical studies necessitate a need for additional studies with more rigorous designs and methodical interpretations in order to measure the potential of the natural agents against PCa.

show abstract

“… 9 In a small clinical trial, castrate-resistant PCa patients taking APC-100, an antioxidant moiety of α-tocopherol, maintained stable disease and median progression-free survival of 2.8 months. 64 In a 6-month clinical trial, high α-tocopherol levels were inversely related to serum PSA levels in biochemical recurrent PCa patients ( n = 39). 14 In contrast, other studies have shown negative effects associated with vitamin E intervention or its circulating plasma levels in PCa patients.…”

Section: Introductionmentioning

confidence: 99%

Nutraceuticals in prostate cancer therapeutic strategies and their neo-adjuvant use in diverse populations

2018

View full text Add to dashboard Cite

Prostate cancer (PCa) is the most frequently diagnosed malignancy and second leading cause of cancer mortality in American males. Notably, men of African descent in the United States and Caribbean have the highest PCa mortality rates compared to men with European ancestry. Although current therapeutics are quite potent and effective, disease resistance, progression to metastasis, therapy-associated toxicities and efficacy-related issues in diverse populations develop over time. Thus, non-toxic and efficacious therapeutic strategies are needed to address these major obstacles for the clinical treatment and management of PCa. In this regard, preclinical and population-based efficacy studies have shown the potential of natural non-toxic nutraceuticals as potent anti-PCa agents. Accordingly, the implementation of nutraceutical intervention and genetic testing in diverse populations might aid in the development and design of precision medicine strategies to reduce the burden of chemotherapy-associated toxicities, suppress disease resistance, and treat both localized and advanced PCa. Consequently, additional large-scale and inclusive clinical studies are required to fully assess efficacy and therapeutic limitations of these agents in PCa. This review discusses the most current clinical research on selected nutraceutical agents and their efficacy in the context of clinico-pathological outcomes and disease susceptibility in diverse PCa clinical and epidemiological studies.

show abstract

A multicenter phase 1/2a dose-escalation study of the antioxidant moiety of vitamin E 2,2,5,7,8-pentamethyl-6-chromanol (APC-100) in men with advanced prostate cancer

Cited by 9 publications

References 20 publications

Oxidative stress and prostatic diseases

Oxidative stress and prostatic diseases

Prostate cancer chemoprevention by natural agents: Clinical evidence and potential implications

Nutraceuticals in prostate cancer therapeutic strategies and their neo-adjuvant use in diverse populations

Contact Info

Product

Resources

About